

Douglas A Rubinson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4951122/publications.pdf>

Version: 2024-02-01

40
papers

5,332
citations

172457

29
h-index

330143

37
g-index

42
all docs

42
docs citations

42
times ranked

8757
citing authors

#	ARTICLE	IF	CITATIONS
1	A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. <i>Nature Genetics</i> , 2003, 33, 401-406.	21.4	1,427
2	Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. <i>Nature Medicine</i> , 2014, 20, 1193-1198.	30.7	510
3	Lamellipodin, an Ena/VASP Ligand, Is Implicated in the Regulation of Lamellipodial Dynamics. <i>Developmental Cell</i> , 2004, 7, 571-583.	7.0	301
4	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2014, 19, 637-638.	3.7	292
5	Filopodia are required for cortical neurite initiation. <i>Nature Cell Biology</i> , 2007, 9, 1347-1359.	10.3	276
6	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. <i>Cancer Discovery</i> , 2018, 8, 1096-1111.	9.4	256
7	Ena/VASP Is Required for Neuritogenesis in the Developing Cortex. <i>Neuron</i> , 2007, 56, 441-455.	8.1	204
8	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. <i>Cell</i> , 2021, 184, 6119-6137.e26.	28.9	201
9	Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2018, 4, e173420.	7.1	155
10	Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. <i>Genetics in Medicine</i> , 2019, 21, 213-223.	2.4	151
11	Effect of High-Dose vs Standard-Dose Vitamin D ₃ Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1370.	7.4	134
12	Critical Roles of Phosphorylation and Actin Binding Motifs, but Not the Central Proline-rich Region, for Ena/Vasodilator-stimulated Phosphoprotein (VASP) Function during Cell Migration. <i>Molecular Biology of the Cell</i> , 2002, 13, 2533-2546.	2.1	117
13	Prediagnostic Body Mass Index and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2013, 31, 4229-4234.	1.6	115
14	Ena/VASP is required for endothelial barrier function in vivo. <i>Journal of Cell Biology</i> , 2007, 179, 761-775.	5.2	103
15	A La protein requirement for efficient pre-tRNA folding. <i>EMBO Journal</i> , 2003, 22, 6562-6572.	7.8	99
16	RNAI AS AN EXPERIMENTAL AND THERAPEUTIC TOOL TO STUDY AND REGULATE PHYSIOLOGICAL AND DISEASE PROCESSES. <i>Annual Review of Physiology</i> , 2005, 67, 147-173.	18.1	96
17	Survival Among Patients With Pancreatic Cancer and Long-Standing or Recent-Onset Diabetes Mellitus. <i>Journal of Clinical Oncology</i> , 2015, 33, 29-35.	1.6	83
18	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. <i>Cancer Discovery</i> , 2021, 11, 2014-2031.	9.4	79

#	ARTICLE	IF	CITATIONS
19	Cigarette Smoking and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2017, 35, 1822-1828.	1.6	78
20	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1069-1081.	7.0	75
21	Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. <i>British Journal of Cancer</i> , 2017, 117, 1874-1882.	6.4	73
22	Diabetes, Weight Change, and Pancreatic Cancer Risk. <i>JAMA Oncology</i> , 2020, 6, e202948.	7.1	72
23	ARF Is Not Required for Apoptosis in Rb Mutant Mouse Embryos. <i>Current Biology</i> , 2002, 12, 159-163.	3.9	70
24	Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies. <i>Oncologist</i> , 2015, 20, 499-507.	3.7	64
25	Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2016, 34, 2899-2905.	1.6	49
26	FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021, 11, 2488-2505.	9.4	46
27	ARF mutation accelerates pituitary tumor development in Rb ^{+/-} mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16865-16870.	7.1	42
28	Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. <i>Investigational New Drugs</i> , 2014, 32, 113-122.	2.6	42
29	Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv409.	6.3	31
30	Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1300-1306.e3.	4.4	21
31	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. <i>Pancreatology</i> , 2021, 21, 1119-1126.	1.1	13
32	Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. , 2021, 9, e002472.		13
33	Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 761-776.	2.2	11
34	Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1586-1595.	2.5	8
35	Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. <i>Cancers</i> , 2020, 12, 3451.	3.7	6
36	Abstract 3036: Real-time genomic characterization of metastatic pancreatic cancer to enable precision medicine. , 2017, , .		3

#	ARTICLE	IF	CITATIONS
37	Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. <i>Oncologist</i> , 2022, 27, 292-298.	3.7	2
38	Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 3133-3140.	1.4	2
39	Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study. <i>BMJ Open Sport and Exercise Medicine</i> , 2022, 8, e001353.	2.9	2
40	Ena/VASP is required for endothelial barrier function in vivo. <i>Journal of Experimental Medicine</i> , 2007, 204, i26-i26.	8.5	0